Study of factor XI deficiency in Khuzestan cattle population of Iran

The present study investigated the occurrence of autosomal recessive genetic disease, factor XI (FXI), in Khuzestan native cows and Iranian Holstein cattle. Genomic DNA was isolated from the blood of the cows (n = 330). Exon 12 of the Factor XI gene of the cows was amplified by polymerase chain reaction (PCR). Additionally, all cows were confirmed by DNA sequencing to determine existence of mutant FXI allele. Normal cattle have only one DNA fragment of 244 bp while heterozygous cattle exhibited two DNA fragments of 320 and 244 bp for the FXI gene deficiency. The results of this study showed that none of the animals were carriers of FXI deficiency. Because of the economical significance of the FXI mutation and its recessive mode of inheritance, attention has to be paid to any case of a bull having in his origin any known FXI carrier. Although we did not observe any carrier, widespread screening programs for detection of genetic disorders seems necessary.Key words: Factor XI, deficiency, sequencing, cattle, Iran

Polymorphism of calpastatin gene in Arabic sheep using PCR- RFLP

Calpastatin has been known as candidate gene in muscle growth efficiency and meat quality. This gene has been located to chromosome 5 of sheep. In order to evaluate the calpastatin gene polymorphism, random blood sample were collected from 111 Arabic ram sheep from different regions. The DNA extraction was based on Boom et al. (1989) method. Exon and entron I from L domain of the ovine calpastatin gene was amplified to produce a 622 bp fragment. The PCR products were electrophoresed on 1.2% agarose gel and stained by etidium bromide. Then, they were digested with restriction enzyme MspI and then electrophoresed on 2.5% agarose gel with ethidium bromide and revealed two alleles, allele A and allele B. Data were analysed using PopGene32 package. In this population, AA, AB, BB genotype have been identified with the 70.27, 28.82, 0.9% frequencies. A and B allele’s frequencies were 0.85, 0.15, respectively. The population was found to follow Hardy-Weinberg equilibrium

Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran

The treatment of dysphoric mania is challenging given the need to treat symptoms of both depression and mania simultaneously without provoking any clinical exacerbation. The newer antiepileptic drugs such as gabapentin, lamotrogine, and carbamazepine are often used as adjuncts to either lithium or valproic acid in the treatment of bipolar disorder. We decided to undertake a monotherapy trial because previous evidence suggested mixed states may be more responsive to anticonvulsants than more traditional antimanic agents. 51 patients with a DSM IV diagnosis of dysphoric mania were randomized to three groups comprising gapbapentin, lamotrogine or carbamazepine and followed for 8 weeks. Psychiatric diagnosis was verified by the structural clinical interview for the DSM-IV (SCID). The MMPI-2 in full was used to assess symptoms at baseline and 8 weeks. All three groups showed significant changes in MMPI-2 scores for depression and mania subscales. Gabapentin showed the greatest change in depression symptom improvement relative to lamotrogine and carbamazepine, respectively. Although manic symptoms improved overall, here were no differences between groups in the degree of manic symptom improvement

Expression of the G1 epitope of bovine ephemeral fever virus G glycoprotein in eukaryotic cells

The envelope glycoprotein (protein G) of bovine ephemeral fever virus (BEFV) has been identified as a plausible vaccine candidate against the BEF disease. In the present study, G1 epitope of the G gly-coprotein gene was cloned in an eukaryotic expression vector, pcDNA3.1(+), under the control of the human cytomegalovirus (CMV) promoter. The pcDNA3.1-G1 construct was transfected into human embryonic kidney 293 (HEK 293) cell line and the expression efficiency was verified by immunofluorescence staining of transfected cells and Western blot analysis. The results indicated that G1 protein was expressed by the recombinant pcDNA3.1-G1 construct in the transfected cells. The recombinant plasmid constructed in this study can be used as a DNA vaccine to evaluate its potential for immunogenicity and protection against BEF virus in animal models

Churg-Strauss syndrome following cessation of allergic desensitization vaccination: a case report

<p>Abstract</p> <p>Introduction</p> <p>Churg-Strauss syndrome is a vasculitis of medium to small sized vessels. Diagnosis is mainly clinical with findings of asthma, eosinophilia, rhinosinusitis and signs of vasculitis in major organs.</p> <p>Case presentation</p> <p>We present a case of a 19-year-old Persian male who developed signs and symptoms of this syndrome related to hyposensitization treatments for allergy control.</p> <p>Conclusions</p> <p>No unifying etiology for the disease can be presented as it is found associated with environmental factors, medications, infections and is even considered a variant of asthma with predisposition to vasculitic involvement. Therefore, it is important to recognize this disease and be aware of underdiagnosis because of emphasis on pathologic evidence. Here, we present a case of allergic desensitization causing Churg-Strauss syndrome in the absence of other known factors.</p

Pyogenic spondylitis

Pyogenic spondylitis is a neurological and life threatening condition. It encompasses a broad range of clinical entities, including pyogenic spondylodiscitis, septic discitis, vertebral osteomyelitis, and epidural abscess. The incidence though low appears to be on the rise. The diagnosis is based on clinical, radiological, blood and tissue cultures and histopathological findings. Most of the cases can be treated non-operatively. Surgical treatment is required in 10–20% of patients. Anterior decompression, debridement and fusion are generally recommended and instrumentation is acceptable after good surgical debridement with postoperative antibiotic cover